Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

Inclusion criteria

• Histologically/cytologically proven prostate adenocarcinoma
• Progression or non response with previous chemotherapy regimen (excluding Taxotere®)
• Received previous mitoxantrone/prednisone or one other chemotherapy regimen including emcyt +/- vinblastine
• Castration levels of testosterone (<50 ng/dL )
• ECOG performance status 0-2
• Laboratory requirements :

• Hematology:

• Neutrophils ≥ 1.5 x 10^9/L
• Hemoglobin > 10 g/dL (prior transfusion permitted).
• Platelets ≥ 100 x 10^9/L
• Hepatic function:

• Total bilirubin < the upper-normal limit of the institution.
• ALAT (SGPT) and ASAT (SGOT) ≤ 1.5 times the upper-normal limit of the institution.
• Renal function:

• Creatinine ≤1.5 times the upper normal limit (i.e., NCI grade ≤1)
• No severe or uncontrolled disease

Exclusion criteria

• Chemotherapy within the last 4 weeks
• Anti-androgen therapy within the last 4 weeks.
• Prior malignancy except the following: adequately treated non-melanomatous skin cancer and superficial bladder cancer from which the patient has been disease-free for >2 years.
• Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.
• Treatment with any other anti-cancer therapy (except LHRH agonists) including any prescribed compounds and/or OTC products for the treatment of prostate cancer must be stopped prior to study entry.
• Other serious illness, psychiatric or medical condition that would not permit the patient to be managed according to the protocol including active uncontrolled infection and significant cardiac dysfunction.